vs
Side-by-side financial comparison of Forestar Group Inc. (FOR) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Forestar Group Inc. is the larger business by last-quarter revenue ($273.0M vs $196.9M, roughly 1.4× Pacira BioSciences, Inc.). On growth, Forestar Group Inc. posted the faster year-over-year revenue change (9.0% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-157.1M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -9.6%).
Forestar Group Inc. is a residential lot development company based in Arlington, Texas. The company has operations in 51 markets in 21 states and delivered 11,518 residential lots during the twelve-month period ended December 31, 2020. The company is publicly traded on the New York Stock Exchange and in October 2017 became a majority-owned subsidiary of D.R. Horton, Inc., the largest homebuilder by volume in the United States since 2002. The company primarily acquires entitled real estate and...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
FOR vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $273.0M | $196.9M |
| Net Profit | $15.4M | — |
| Gross Margin | 20.1% | 79.5% |
| Operating Margin | 7.6% | 1.2% |
| Net Margin | 5.6% | — |
| Revenue YoY | 9.0% | 5.1% |
| Net Profit YoY | -6.7% | — |
| EPS (diluted) | $0.30 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $273.0M | $196.9M | ||
| Q3 25 | $670.5M | $179.5M | ||
| Q2 25 | $390.5M | $181.1M | ||
| Q1 25 | $351.0M | $168.9M | ||
| Q4 24 | $250.4M | $187.3M | ||
| Q3 24 | $551.3M | $168.6M | ||
| Q2 24 | $318.4M | $178.0M | ||
| Q1 24 | $333.8M | $167.1M |
| Q4 25 | $15.4M | — | ||
| Q3 25 | $86.9M | $5.4M | ||
| Q2 25 | $32.9M | $-4.8M | ||
| Q1 25 | $31.6M | $4.8M | ||
| Q4 24 | $16.5M | — | ||
| Q3 24 | $81.5M | $-143.5M | ||
| Q2 24 | $38.7M | $18.9M | ||
| Q1 24 | $45.0M | $9.0M |
| Q4 25 | 20.1% | 79.5% | ||
| Q3 25 | 22.3% | 80.9% | ||
| Q2 25 | 20.4% | 77.4% | ||
| Q1 25 | 22.6% | 79.7% | ||
| Q4 24 | 22.0% | 78.7% | ||
| Q3 24 | 23.9% | 76.9% | ||
| Q2 24 | 22.5% | 75.1% | ||
| Q1 24 | 24.9% | 71.6% |
| Q4 25 | 7.6% | 1.2% | ||
| Q3 25 | 16.9% | 3.5% | ||
| Q2 25 | 11.2% | 4.7% | ||
| Q1 25 | 11.6% | 1.2% | ||
| Q4 24 | 8.7% | 13.2% | ||
| Q3 24 | 19.7% | -82.8% | ||
| Q2 24 | 16.2% | 15.9% | ||
| Q1 24 | 17.6% | 7.9% |
| Q4 25 | 5.6% | — | ||
| Q3 25 | 13.0% | 3.0% | ||
| Q2 25 | 8.4% | -2.7% | ||
| Q1 25 | 9.0% | 2.8% | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 14.8% | -85.1% | ||
| Q2 24 | 12.2% | 10.6% | ||
| Q1 24 | 13.5% | 5.4% |
| Q4 25 | $0.30 | $0.05 | ||
| Q3 25 | $1.70 | $0.12 | ||
| Q2 25 | $0.65 | $-0.11 | ||
| Q1 25 | $0.62 | $0.10 | ||
| Q4 24 | $0.32 | $0.38 | ||
| Q3 24 | $1.59 | $-3.11 | ||
| Q2 24 | $0.76 | $0.39 | ||
| Q1 24 | $0.89 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $211.7M | $238.4M |
| Total DebtLower is stronger | $793.2M | $372.2M |
| Stockholders' EquityBook value | $1.8B | $693.1M |
| Total Assets | $3.2B | $1.3B |
| Debt / EquityLower = less leverage | 0.44× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $211.7M | $238.4M | ||
| Q3 25 | $379.2M | $246.3M | ||
| Q2 25 | $189.2M | $445.9M | ||
| Q1 25 | $174.3M | $493.6M | ||
| Q4 24 | $132.0M | $484.6M | ||
| Q3 24 | $481.2M | $453.8M | ||
| Q2 24 | $359.2M | $404.2M | ||
| Q1 24 | $416.2M | $325.9M |
| Q4 25 | $793.2M | $372.2M | ||
| Q3 25 | $802.7M | $376.7M | ||
| Q2 25 | $872.8M | $580.5M | ||
| Q1 25 | $872.5M | $583.4M | ||
| Q4 24 | $806.8M | $585.3M | ||
| Q3 24 | $706.4M | — | ||
| Q2 24 | $706.1M | — | ||
| Q1 24 | $705.7M | — |
| Q4 25 | $1.8B | $693.1M | ||
| Q3 25 | $1.8B | $727.2M | ||
| Q2 25 | $1.7B | $757.8M | ||
| Q1 25 | $1.6B | $798.5M | ||
| Q4 24 | $1.6B | $778.3M | ||
| Q3 24 | $1.6B | $749.6M | ||
| Q2 24 | $1.5B | $879.3M | ||
| Q1 24 | $1.5B | $892.2M |
| Q4 25 | $3.2B | $1.3B | ||
| Q3 25 | $3.1B | $1.3B | ||
| Q2 25 | $3.1B | $1.5B | ||
| Q1 25 | $3.0B | $1.6B | ||
| Q4 24 | $3.0B | $1.6B | ||
| Q3 24 | $2.8B | $1.5B | ||
| Q2 24 | $2.7B | $1.6B | ||
| Q1 24 | $2.6B | $1.6B |
| Q4 25 | 0.44× | 0.54× | ||
| Q3 25 | 0.45× | 0.52× | ||
| Q2 25 | 0.52× | 0.77× | ||
| Q1 25 | 0.53× | 0.73× | ||
| Q4 24 | 0.50× | 0.75× | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.47× | — | ||
| Q1 24 | 0.48× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-157.0M | $43.7M |
| Free Cash FlowOCF − Capex | $-157.1M | $43.5M |
| FCF MarginFCF / Revenue | -57.5% | 22.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | -10.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $93.0M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-157.0M | $43.7M | ||
| Q3 25 | $256.3M | $60.8M | ||
| Q2 25 | $15.8M | $12.0M | ||
| Q1 25 | $-19.8M | $35.5M | ||
| Q4 24 | $-450.0M | $33.1M | ||
| Q3 24 | $119.2M | $53.9M | ||
| Q2 24 | $-61.7M | $53.2M | ||
| Q1 24 | $-59.2M | $49.1M |
| Q4 25 | $-157.1M | $43.5M | ||
| Q3 25 | $255.6M | $57.0M | ||
| Q2 25 | $15.0M | $9.3M | ||
| Q1 25 | $-20.5M | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | $118.4M | $49.8M | ||
| Q2 24 | $-62.3M | $51.6M | ||
| Q1 24 | $-59.8M | $46.3M |
| Q4 25 | -57.5% | 22.1% | ||
| Q3 25 | 38.1% | 31.7% | ||
| Q2 25 | 3.8% | 5.1% | ||
| Q1 25 | -5.8% | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | 21.5% | 29.6% | ||
| Q2 24 | -19.6% | 29.0% | ||
| Q1 24 | -17.9% | 27.7% |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.1% | 2.2% | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.2% | 5.1% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.1% | 2.4% | ||
| Q2 24 | 0.2% | 0.9% | ||
| Q1 24 | 0.2% | 1.7% |
| Q4 25 | -10.19× | — | ||
| Q3 25 | 2.95× | 11.20× | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | -0.63× | 7.37× | ||
| Q4 24 | -27.27× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | -1.59× | 2.82× | ||
| Q1 24 | -1.32× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
